暂无数据
暂无数据
快讯 | BMO Capital重申Acrivon Therapeutics的跑赢大盘,维持25美元的目标股价
分析师提供有关医疗保健公司的见解:Acrivon Therapeutics, Inc.(ACRV)、Arcutis Biotherapeutics(ARQT)和TruBridge(TBRG)
HC Wainwright & Co. 维持Acrivon Therapeutics的买入态度
HC Wainwright & Co. 维持Acrivon Therapeutics的买入态度
分析师提供有关医疗保健公司的见解:Shattuck Labs(STTK)和Acrivon Therapeutics, Inc.(ACRV)
快讯 | Acrivon Therapeutics, Inc.:H.C. Wainwright将目标价格从20美元上调至22美元
Acrivon Therapeutics 第一季度亏损/73c >ACRV
Acrivon Therapeutics 第一季度亏损/73c >ACRV
暂无数据
JESSE JAMES8832 : i expeced so much better for this
JESSE JAMES8832 : maybe fill that gap to 6.62?
Trytosaveabit楼主 JESSE JAMES8832: Yup! But look at PCSA! It gets just a PT increase and flyin! This gets great news and a PT increase and dud? Hehehe
Trytosaveabit楼主 JESSE JAMES8832: It might try?